CDTX: Cidara Company Value to Net Income

cidara.com - graphic logo of issuer CDTX

What are the growth horizons for Cidara Therapeutics (CDTX) given its high concentration on immunotherapy? The answer is provided by the company's price-to-earnings trend, where -35.50 marks a new level. Current capital is based on grants and partner payments while the company's own profit stream is being established. Strict compliance with environmental standards in the development of antifungal agents completes the business profile.

CDTX - Cidara Therapeutics Inc P/E Multiple over the range 07/04/2022 - 01/17/2026

Analytical breakdowns for Cidara Therapeutics (CDTX)

- price and consensus price forecast:
Stock Price Cidara Therapeutics Corp|CDTX - Consensus Target
- market capitalization information:
Market Value Cidara Therapeutics, Inc.|CDTX - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Cidara|CDTX - Book Capitalization|Market Capitalization to Book Value cidara.com|CDTX - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Cidara Therapeutics|CDTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital cidara.com|CDTX - Company Debts|Debts to Net Assets Cidara Therapeutics, Inc.|CDTX - Company Long-Term Debts|Company Current Liabilities Cidara|Interim Coverage Ratio cidara.com
- earnings and market ratios statistics:
CDTX - Net Profit|Net Profit Forecast Cidara Therapeutics|CDTX - P/E Multiple|Forward P/E Multiple Cidara Therapeutics Inc|CDTX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Cidara Therapeutics, Inc.|CDTX - Operating profit EBITDA|Net earnings per share (EPS TTM) Cidara|CDTX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months cidara.com|CDTX - Net earnings per share growth this year|Projected earnings per share increase next year Cidara Therapeutics
- company sales and revenue statistics:
CDTX - Revenue and Sales Volume|Company Future Revenue Cidara Therapeutics|CDTX - P/S Multiple|Market Cap to Future Revenue Ratio Cidara Therapeutics, Inc.
Comprehensive company analysis:Cidara Therapeutics
Flagship merchandise of Cidara Therapeutics

Cidara Therapeutics (CDTX) operates within an autonomous innovative drug development cycle, rendering its business resilient to macroeconomic shocks. By analyzing the company's trailing P/E, an investor assesses the ratio of the stock's market value to net income, determining the degree of overvaluation and the price margin of safety during periods of market volatility.

Key competitors

P/E Multiple gilead.com|Price to Earnings Ratio NVAX (Novavax)|CVAC (CureVac NV) - Company Value to Net Income|Valneva Pharma - Price to Earnings Ratio|Vir Corp - Price to Earnings Ratio|SIGA Technologies, Inc. - P/E Multiple|Business Payback Period emergentbiosolutions.com EBS|Atea Pharmaceuticals, Inc. (AVIR) - Price to Earnings Ratio|Invivyd - Company Value to Net Income|Price to Earnings Ratio ENTA|P/E Multiple Inovio Pharma|Price to Earnings Ratio HilleVax, Inc. (HLVX)|Business Payback Period kalaristx.com|P/E Multiple DYAI (Dyadic International, Inc.)|NNVC - Price to Earnings Ratio|Talphera Corp - P/E Multiple|Business Payback Period Cocrystal Pharma Corp COCP|TRAW: P/E Multiple|Price to Earnings Multiple DWTX|QLGN (Qualigen Therapeutics, Inc.) - P/E Multiple|P/E Multiple AlloVir Bio|Price to Earnings Ratio VBI Vaccines Inc. (VBIV)|VIRI (virios.com) - Company Value to Net Income|P/E Multiple VXRT (Vaxart)